eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 5
Review paper

Clinical aspects of sodium butyrate application in dietary treatment of bowel diseases

Tomasz Banasiewicz, Katarzyna Borycka-Kiciak, Agnieszka Dobrowolska-Zachwieja, Jerzy Friediger, Adam Kiciak, Piotr Krokowicz, Ewa Małecka-Panas, Piotr Pietrzak, Grażyna Rydzewska, Wiesław Tarnowski, Romuald Zabielski

Przegląd Gastroenterologiczny 2010; 5 (6): 329–334
Online publish date: 2010/12/08
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
This article presents the point of view of a group of experts in physiology, gastroenterology and surgery regarding effectiveness of butyric acid preparation in dietary treatment in patients with small and large bowel diseases. The literature review revealed that butyric acid given per os as sodium salt (sodium butyrate) has a number of beneficial effects on function and regeneration of intestines. The dietary product of special medicinal use Debutir™ (Polfa-Łódź) contains sodium butyrate as an active substance, protected in a triglyceride matrix, which allows slow release of sodium butyrate along the entire gastrointestinal tract, thereby permitting its positive effects to be exerted on the entire small and large bowel. Experts have pointed out the clinical need to introduce butyric acid and its salt in dietary treatment in patients with intestine diseases. Experts have specified several groups of patients who would gain special benefits from enriching the diet with butyric acid. Use of butyric acid preparations is recommended for elderly people, and for patients with irritable bowel disease (IBD), after intestine resection and pouchitis. The strong trophic effect of sodium butyrate justifies its use in patients with cancer cachexia, with chronic diseases and immunity disturbances.

sodium butyrate, Crohn’s disease, irritable bowel syndrom


Roediger WEW. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 1980; 21: 793-8.  

Roy CC, Kien CL, Bouthillier L, et al. Short-chain fatty acids: ready for prime time? Nutr Cl Prac 2006; 21: 351-66.  

Scheppach W, Bartram P, Richter A, et al. Effect of short-chain fatty acids on the human colonic mucosa in vitro. J Parenter Enter Nutr 1992; 16: 43-8.  

Kotunia A, Pietrzak P, Guilloteau P, et al. Kwas masłowy w przewodzie pokarmowym. Przegląd Gastroenterologiczny 2010; 5: 117-22.  

Banasiewicz T, Borycka-Kiciak K, Kiciak A, et al. Kwas masłowy w zapaleniach jelit. Przegląd Gastroenterologiczny 2010; 5: 251-7.  

Smyth HF Jr, Carpenter CP, Weil CS, et al. Range-finding toxicity data: list V. AMA Arch Ind Hyg Occup Med 1954; 10: 61-8.  

Senagore AJ, MacKeigan JM, Scheider M, et al. Short-chain fatty acid enemas: a cost-effective alternative in the treatment of nonspecific proctosigmoiditis. Dis Colon Rectum 1992; 35: 923-7.  

Breuer RI, Soergel KH, Lashner BA, et al. Short-chain fatty acid rectal irrigation for left-side ulcerativecolitis: a randomized, placebo-controlled trial. Gastroenterology 1996; 110: 873.  

Andoh A, Bamba T, Sasaki M. Physiological and anti-inflamatory roles of diatery fiber and butyrate in intestinal functions. J Parent Ent Nutr 1999; 23: 70-3.

. Claus R, Günthner D, Letzguß H. Effects of feeding fat-coated butyrate on mucosal morphology and function in the small intestine of the pig. J Anim Physiol Anim Nutr 2007; 91: 312-8.

Thompson JS, Quigley EM, Palmer JM, et al. Luminal short-chain fatty acidsand postresection intestinal adaptation. J Parenter Enteral Nutr 1996; 20: 338-43.

Jeppesen PB, Mortensen PB. Enhancing bowel adaptation in short bowel syndrome. Curr Gastroenterol Rep 2002; 4: 338-47.

. Galfi P, Bokori J. Feeding trial in pigs with a diet containing sodium n-butyrate. Acta Veterinaria Hungarica 1990; 38: 3-17.

. D’Argenio G, Cosenza V, Delle Cave M, et al. Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat model. Gastroenterology 1996; 110: 1727-34.

Tedelind S, Westberg F, Kjerrulf M, et al. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 2007; 13: 2826-32.

Meier-Ruge WA, Ammann K, Bruder E, et al. Updated results on intestinal neuronal dysplasia (IND B). Eur J Pediatr Surg 2004; 14: 384-91.

Peng L, He Z, Chen W, et al. Effects of butyrate on intestinal barrier function in Caco-2 cell monolayer model of intestinal barrier. Pediatr Res 2007; 61: 37-41.

McIntyre A, Gibson PR, Young GP. Butyrate production from diatery fiber and protection against large bowel cancer in rat model. Gut 1993; 34: 386-91.

Velázquez OC, Ledered HM, Rombeau JL. Butyrate and the colonocyte, implication for neoplasia. Dig Dis Sci 1996; 41: 727-39.

Leder A, Leder P. Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells. Cell 1975; 5: 319-22.

Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in SCD. Blood 1999; 93: 1790-9.

Weinberg R, Ji X, Sutton M, et al. Butyrate increase the efficiency of translation of -globin mRNA. Blod 2005; 105: 1807-9.

Pinto A, Fidalgo P, Cravo M, et al. Short chain fatty acids are effective in short-term treatment of chronic radiation proctitis: randomized, double-blind, controlled trial. Dis Colon Rectum 1999; 42: 788-95; discussion 795-6.

Al-Sabbagh R, Sinicrope F, Sellin J, et al. Short-chain fatty acid (SCFA) enemas for radiation colitis. Gastroenterology 1994; 106: A2.

Mamel JJ, Chen M, Combs W, et al. Short-chain fatty acid (SCFA) enema are useful for treatment of chronic radiation proctitis (CRP). Gastroenterolgy 1995; 108: A305.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe